TMDX Stock Recent News

The company's unique FDA-approved multi-organ platform and proprietary aviation division enhance its competitive edge, reducing costs and improving surgical outcomes. While there are risks, including liquidity and potential competition, the long-term benefits and market position make TransMedics a compelling buy-and-hold investment. And most importantly, it is a product that could lead to a huge moat in the advancement of human medicine.

ANDOVER, Mass. , Oct. 15, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2024 after market close on Monday, October 28, 2024.

On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 2,281,896 shares of TransMedics Group Inc (TMDX, Financial), a leader in advanced organ transplant technology. This move reduced FMR LLC (Trades, Portfolio)'s holdings in the company by 50.82%, leaving them with a total of 2,208,308 shares.

The mean of analysts' price targets for TransMedics (TMDX) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

ANDOVER, Mass. , Sept. 27, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on September 24, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 336 shares of its common stock and an aggregate of 218 restricted stock units to 1 employee, each as a material inducement for the employee's entry into employment with TransMedics.

TransMedics is revolutionizing organ transportation with its FDA-approved Organ Care System, improving organ functionality during transport. Significant investments in logistics, including owning aircraft, enhancing its moat, reducing graft dysfunction by 50% and improving donation effectiveness. The company has a strong competitive edge, evident in its 100%+ YoY sales growth and 10-12% net margins, yet trades at a lower EV/Sales multiple than peers.

TransMedics' one-year beta is ballooning, meaning the stock is becoming increasingly more volatile. Furthermore, a growing number of traders are betting against the stock.

Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

ANDOVER, Mass. , Aug. 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York.